Combined Measurements of Cardiac Troponin I and Brain Natriuretic Peptide Are Useful for Predicting Adverse Outcomes in Hypertrophic Cardiomyopathy
-
- Kubo Toru
- Department of Medicine and Geriatrics, Kochi Medical School
-
- Kitaoka Hiroaki
- Department of Medicine and Geriatrics, Kochi Medical School
-
- Okawa Makoto
- Department of Medicine and Geriatrics, Kochi Medical School
-
- Yamanaka Shigeo
- Department of Laboratory Medicine, Kochi Medical School
-
- Hirota Takayoshi
- Department of Medicine and Geriatrics, Kochi Medical School
-
- Baba Yuichi
- Department of Medicine and Geriatrics, Kochi Medical School
-
- Hayato Kayo
- Department of Medicine and Geriatrics, Kochi Medical School
-
- Yamasaki Naohito
- Department of Medicine and Geriatrics, Kochi Medical School
-
- Matsumura Yoshihisa
- Department of Medicine and Geriatrics, Kochi Medical School
-
- Yasuda Nobufumi
- Department of Public Health, Kochi Medical School
-
- Sugiura Tetsuro
- Department of Laboratory Medicine, Kochi Medical School
-
- Doi Yoshinori L.
- Department of Medicine and Geriatrics, Kochi Medical School
Search this article
Abstract
Background: Although serum cardiac troponin I (cTnI) and plasma brain natriuretic peptide (BNP) have become clinically important tools as diagnostic and prognostic markers for ischemic heart disease and heart failure, the usefulness of these biomarkers for risk stratification of hypertrophic cardiomyopathy (HCM) is not clear. Methods and Results: We studied 167 patients with HCM, and cTnI and BNP were measured. During follow-up (38.5 months), 20 patients suffered from cardiovascular events: HCM-related deaths in 6, hospitalization for heart failure in 8, embolic stroke in 5 and 1 patient with spontaneous sustained ventricular tachycardia. Patients with high cTnI values (≥0.04ng/ml) had more frequent cardiovascular events than did those with low cTnI values (P=0.008). Similarly, there were more frequent adverse events in the high BNP group (≥200pg/ml) than in the low BNP group (P=0.002). When groups were allocated according to both cTnI and BNP measurements, serum cTnI used in conjunction with BNP further improved the prognostic value; patients with both high cTnI and BNP values had an 11.7-fold increased risk of cardiovascular events compared with those with both low cTnI and BNP values. Conclusions: CTnI and BNP are useful parameters for identifying patients at risk for clinical deteriorations, and combined measurements of these biomarkers further improves the prognostic value of increased cardiovascular events in HCM. (Circ J 2011; 75: 919-926)<br>
Journal
-
- Circulation Journal
-
Circulation Journal 75 (4), 919-926, 2011
The Japanese Circulation Society
- Tweet
Details 詳細情報について
-
- CRID
- 1390282680078809600
-
- NII Article ID
- 10028103447
-
- NII Book ID
- AA11591968
-
- ISSN
- 13474820
- 13469843
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed